002382 Blue Sail Medical
- 5.72
- -0.06-1.04%
Blue Sail Medical News
Lanfan Medical (002382.SZ) subsidiary Xinqi coronary balloon dilatation catheter obtained NMPA registration in China
Lanfan Medical (002382.SZ) announced that Shanghai Lanfan Boyuan Medical Technology, a subsidiary of the company's cardiovascular division...
Lanfan Medical (002382.SZ): Subsidiary Xinqi Coronary Balloon Expansion Catheter obtained China NMPA registration
Gelonghui, May 8, 丨 Lanfan Medical (002382.SZ) announced that recently, Lanfan Medical Co., Ltd. received a notice that the three types of medical devices developed and produced by Shanghai Lanfan Boyuan Medical Technology Co., Ltd., a subsidiary of the company's cardiovascular division, were approved and registered by the National Drug Administration (NMPA).
Express News | Lanfan Medical: Subsidiary Xinqi Coronary Balloon Dilation Catheters obtained Chinese NMPA registration
Express News | Blue Sail Healthcare: The second quarter performance of the Protection Division is expected to improve further significantly
Lanfan Healthcare (002382.SZ) announced first-quarter results with a net loss of 98.9196 million yuan
According to the Zhitong Finance App, Lanfan Healthcare (002382.SZ) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 1,455 billion yuan, an increase of 32.96% over the previous year. The net loss attributable to shareholders of the listed company was RMB 98.9196 million. Net loss of $124 million after deducting non-recurring profit and loss attributable to shareholders of listed companies.
Some directors and executives of Lanfan Healthcare (002382.SZ) increased their total holdings of the company's shares by 973,300
Lanfan Medical (002382.SZ) issued an announcement. As of the disclosure date of this announcement, Ms. Liu Wenjing and Mr. Shu Qiao, at...
Express News | Lanfan Healthcare: Some directors and senior management plan to increase their holdings by 4 million yuan to 8 million yuan
Blue Sail Medical (002382.SZ): initial repurchase of 361,600 shares
Gelonghui, March 17, 丨 Lanfan Medical (002382.SZ) announced that on March 15, 2024, for the first time, the company repurchased 361,600 shares of the company's shares through a special stock repurchase securities account, accounting for 0.0359% of the company's total share capital. The highest transaction price was 5.56 yuan/share, the minimum transaction price was 5.49 yuan/share, and the total transaction amount was RMB 1,996,619.00 (excluding transaction fees).
Express News | More than 10 listed companies disclosed repurchase plans after the market and announced Hisense Video plans to repurchase shares of up to 750 million yuan
Express News | Blue Sail Surgical Electric Endoscopic Stapler Approved by EU CE MDR Certification
Express News | Lanfan Medical said on an interactive platform on February 29 that up to now, the company's controlling shareholder's stock pledge risk is within a manageable range.
Southwest Securities: There is still a lot of room for penetration in the coronary artery disease interventional treatment market, focus on Sano Healthcare (688108.SH), etc.
Coronary heart disease is the leading cause of death in the world, and there is still plenty of room for penetration in the interventional treatment market for coronary artery disease in China.
Express News | More than 20 listed companies disclosed plans to repurchase or increase their holdings after the market and announced that Zhouwei Foods plans to repurchase shares of up to 300 million yuan
Lanfan Medical (002382.SZ): Plans to spend 25 million yuan to 50 million yuan to buy back shares
Gelonghui, Feb. 21丨Lanfan Healthcare (002382.SZ) announced that the company plans to use its own funds to repurchase some RMB common stock (A shares) shares issued by the company through centralized bidding transactions, which are necessary to protect the company's value and shareholders' rights. The total amount of capital to be used for the repurchase shall not be less than RMB 25 million (including the principal amount) and not more than RMB 50 million (including the principal amount), and the repurchase price shall not exceed RMB 8.60 per share (including the principal amount). The specific total amount of repurchase funds is based on the total amount of funds actually used for the repurchase at the end of the repurchase. According to the total amount of capital to be used for this repurchase, the maximum number of people
Lanfan Medical (002382.SZ): Actual controller Li Zhenping completed an increase of 2.572,100 shares
Gelonghui, February 19, 丨 Lanfan Medical (002382.SZ) announced that on February 19, 2024, the company received a “Notice Letter on the Implementation Results of the Plan to Increase Shareholding” from the actual controller, Mr. Li Zhenping. As of the announcement disclosure date, Mr. Li Zhenping's current plan to increase his holdings had been completed. From February 8, 2024 to February 19, 2024, Mr. Li Zhenping increased his holdings of the company's shares by 2,5720.82 million shares through centralized bidding through the Shenzhen Stock Exchange trading system, accounting for 0.26% of the company's total share capital. The total increase in holdings was RMB 12.20.1 million.
Express News | Lanfan Healthcare: The actual controller plans to increase the company's shares by no less than 10 million yuan
Lanfan Healthcare (002382.SZ): Pre-loss of 510 million yuan to 610 million yuan in 2023
Gelonghui, January 30 | Lanfan Healthcare (002382.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 51 million yuan to 61 million yuan, down 36.98%-63.84% from the same period last year; net profit loss after deducting non-recurring profit and loss ratio of 58,000 yuan to 68,000 yuan; basic earnings loss per share of 0.51 yuan/share - 0.61 yuan/share. During the reporting period, the company's net profit after deducting non-recurring profit and loss did not change much compared to the same period last year, which is expected to reflect an increase of 11.74% in losses
Lanfan Healthcare (002382.SZ): Lanfan Baisheng plans to increase capital and expand shares to introduce strategic investors
Gelonghui, January 25丨Lanfan Medical (002382.SZ) announced that Beijing Lanfan Baisheng Medical Technology Co., Ltd. (“Lanfan Baisheng”), the company's cardiovascular business entity and wholly-owned subsidiary, plans to introduce strategic investors Capital Health Industry (Beijing) Fund (limited partnership) (“Capital University Health Industry Fund”), Hebei Linkong Private Equity Fund Management Co., Ltd. (“Linkong Private Equity Fund”) and Linqu County High-tech Industry Investment Co., Ltd. (“High-tech Industry Investment”) (collectively, the “Investors”) Stock expansion, as agreed by all parties Confirmed that the investor intends to use cash
Blue Sail Medical (002382.SZ): Health gloves, masks, disinfectant wipes and other products can effectively protect themselves and are eligible for export
Gelonghui, January 23 | Lanfan Medical (002382.SZ) said on the investor interactive platform that the company's products such as health gloves, masks, and disinfectant wipes can effectively protect themselves and have export qualifications, and can be used as protective materials. The company will continue to pay attention to the development of related matters. If relevant regions increase procurement of these products, companies can guarantee supply and export in a timely manner.
Blue Sail Medical (002382.SZ): “Invisible Mask” Blue Sniper Nano Antibody Anti-Crown Spray is the company's patented product
Gelonghui, January 23 | Lanfan Medical (002382.SZ) said on the investor interactive platform that the “invisible mask” Blue Sniper nano antibody anti-crown spray is the company's patented product. It forms a protective layer on the nasal mucosa in the form of a nasal spray to effectively block viral invasion and infection. There are other competitors in this field, but since the launch on May 5, 2023, the company's products have surpassed similar products in a month and reached the leading position in this category.
Analysis
Price Target
No Data
